Prescription RequiredMidostaurin is a targeted cancer medicine used for FLT3-mutated acute myeloid leukaemia and selected forms of advanced systemic mastocytosis. It may be combined with chemotherapy for AML or used according to a specialist treatment plan for mast-cell disorders.
| Generic Name | Midostaurin |
| Strength | 25 mg |
| Manufacturer | Zydus |
| Packing | 28 Capsules |
| Prescribed For | Acute Myeloid Leukemia (AML) |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries. |
| Package | USD | GBP | AUD | NZD | PHP | KRW | RON | HKD | MYR | THB | AED |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 Capsules | $90 | £67 | A$126 | NZ$157 | ₱5,635 | ₩121,455 | lei 410 | HK$706 | RM367 | ฿2,940 | د.إ331 |
Midostaurin blocks several protein kinases that send signals encouraging abnormal cells to survive and multiply. These include abnormal FLT3 activity in certain forms of acute myeloid leukaemia. Blocking these signals helps control cancer-cell growth and promotes their death.
Disclaimer
This website operates in compliance with applicable pharmaceutical laws. All content and data available on this website are intended solely for informational purposes. The information provided is not a substitute for professional medical advice, diagnosis, or treatment. Information provided here is for general awareness and does not replace medical advice. We strongly encourage you to consult a qualified healthcare professional for guidance.
